Skip to content
Pharmacy Glow

GLOW peptide: the source shelf

The experiments, reviews and regulatory documents behind these pages.

Where I return when a claim sounds too easy

The rat tendon paper and rat wound paper reward attention to their experimental subjects. The hair trial rewards attention to the other active ingredient. The topical GHK review puts the skin barrier back in the picture.

I return to those particulars when a general benefit claim feels too smooth. The FDA documents serve a different purpose: they describe regulatory categories, concerns and advisory materials. An experimental result cannot replace that record, and the record cannot establish clinical benefit. The complete reading list follows.

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Res Int. 2015;2015:648108. ↗
  2. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. ↗
  3. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  4. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
  6. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438-443. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. ↗
  9. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA, Human Drug Compounding (nominated-but-withdrawn entries for BPC-157; 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; and 'GHK-Cu (for injectable routes of administration)'; FDA safety concerns remain listed). ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, Human Drug Compounding (definitions of Category 1 and Category 2; 503A/503B bulks-list and nomination framework). ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar (BPC-157, KPV, TB-500, and MOTs-C listed as substances being considered for inclusion on the 503A Bulks List; GHK-Cu not on the agenda). ↗
  14. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated. FDA, Cosmetics Laws & Regulations (basis for the cosmetic-vs-drug distinction underlying topical 'Copper Tripeptide-1'). ↗
  15. Ruff D, et al.. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:118-122. ↗
  16. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. ↗